WHWK (Whitehawk Therapeutics) Interest Expense : $-0.15 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Whitehawk Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Whitehawk Therapeutics's interest expense for the three months ended in Dec. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.15 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Whitehawk Therapeutics's Operating Income for the three months ended in Dec. 2024 was $ -18.95 Mil. Whitehawk Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $ 0.00 Mil. GuruFocus does not calculate Whitehawk Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Whitehawk Therapeutics Interest Expense Historical Data

The historical data trend for Whitehawk Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Whitehawk Therapeutics Interest Expense Chart

Whitehawk Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

-0.82

-0.67

-0.23

-0.15

Whitehawk Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial													-0.06	-0.06	-0.06	-0.04	-

Whitehawk Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.15 Mil.

Whitehawk Therapeutics (NAS:WHWK) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Whitehawk Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-18.95 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $0.57 Mil.

Whitehawk Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate Whitehawk Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Whitehawk Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Whitehawk Therapeutics Inc (NAS:WHWK) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

3350:Germany

Address

2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey, NJ, USA, 07960

Website

https://www.whitehawktx.com

Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.

Executives

David James Lennon	director, officer: Chief Executive Officer	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD, SUITE A250, PACIFIC PALISADES CA 90272
Scott M. Giacobello	officer: Chief Financial Officer	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Neil Desai	director, officer: See Remarks	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Mohammad Hirmand	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Lorettta M Itri	officer: Chief Medical Officer
Brendan Delaney	officer: Chief Operating Officer	300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Emma Reeve	director	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Karin M. Hehenberger	director	C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON CO 01803
Richard E Maroun	director	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Lance E Thibault	officer: Chief Financial Officer
Behzad Aghazadeh	director, other: See Remarks	C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Venbio Select Advisor Llc	director, other: See Remarks	110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Anupam Dalal	director	88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Avoro Ventures Llc	director, other: See Remarks	110 GREEN STREET, SUITE 800, NEW YORK NY 10012